Clinical Trials Logo

Clinical Trial Summary

Background: People with COVID-19 have varying degrees of illness. It can range from no or mild symptoms to critical illness and death. Some people with COVID-19 have long-term effects regardless of the severity of their disease initially. Researchers want to learn more to see if they can better predict where a person may fall on the illness spectrum. Objective: To follow and record symptoms of COVID-19 to see how it progresses in people and why some people stay sick longer than others. Eligibility: People ages 18-65 who received a COVID-19 positive test result in the 72 hours before their enrollment in the study. Design: Participants will complete a 30-minute baseline survey. They will answer questions about themselves and their health. Participants will get a digital wristband and temperature sensor in the mail. They will get instructions on how to set up and wear the devices. They will download a mobile application on their phone. The app will collect data from the devices. Participants will wear the wristband and sensor every day for the first month. Then they will wear the devices for a total of 40 days over the next 5 months. On the days they wear the devices, they will answer a 2-question health survey via the app. Participants will answer a 20-minute online survey about their health every 30 days. If participants are hospitalized, a family member or close friend will be asked to complete a brief 7-minute online survey about their hospital stay and treatment. Participants will be sent alerts and reminders throughout the study. Participation will last for 6 months.


Clinical Trial Description

Study Description: COVID-19 patients experience varying degrees of illness. Factors associated with prolonged illness remain unknown especially in non-hospitalized patients. This study uses digital wearables to collect high-resolution physiological data to understand the clinical course of COVID-19 in patients with a positive COVID-19 diagnosis. We hypothesize that wearables-based physiological data are associated with COVID-19 post-acute sequelae. Objectives: To identify digital wearables-based physiological data that are associated with COVID-19 post-acute sequelae. Endpoints: Primary endpoint: Long COVID-19 defined as >=1 symptom at 3 weeks beyond first symptom onset or test positivity, whichever comes first. Secondary endpoint: Chronic COVID-19 defined as >=1 symptom at 12 weeks beyond first symptom onset or test positivity, whichever comes first. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04927442
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Sherine M El-Toukhy, Ph.D.
Phone (301) 594-4743
Email sherine.el-toukhy@nih.gov
Status Recruiting
Phase
Start date October 11, 2021
Completion date April 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed NCT05305508 - Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19. Phase 2
Completed NCT04932850 - Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease. Phase 1
Completed NCT04753762 - Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection
Recruiting NCT06259578 - UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study) Early Phase 1
Withdrawn NCT05085574 - Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Phase 2
Active, not recruiting NCT05077332 - LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Phase 2
Terminated NCT05077969 - Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) Phase 2